Role of disulfide linkage in action of bis(dialkylaminethiocarbonyl)disulfides as potent double-Edged microbicidal spermicide: Design, synthesis and biology

Sperm Toolbox-A selection of small molecules to study human spermatozoa

Male contraceptive options and infertility treatments are limited, and almost all innovation has been limited to updates to medically assisted reproduction protocols and methods. To accelerate the development of drugs that can either improve or inhibit fertility, we established a small molecule library as a toolbox for assay development and screening campaigns using human spermatozoa. We have profiled all compounds in the Sperm Toolbox in several automated high-throughput assays that measure stimulation or inhibition of sperm motility or the acrosome reaction. We have assayed motility under non-capacitating and capacitating conditions to distinguish between pathways operating under these different physiological states. We also assayed cell viability to ensure any effects on sperm function are specific. A key advantage of our studies is that all compounds are assayed together in the same experimental conditions, which allows quantitative comparisons of their effects in complementary functional assays. We have combined the resulting datasets to generate fingerprints of the Sperm Toolbox compounds on sperm function. The data are included in an on-line R-based app for convenient querying.

Vaginitis: Review on Drug Resistance

Female genital tract infections have a high incidence among different age groups and represent an important impact on public health. Among them, vaginitis refers to inflammation of the vulva and/or vagina due to the presence of pathogens that cause trichomoniasis, bacterial vaginosis, and vulvovaginal candidiasis. Several discomforts are associated with these infections, as well as pregnancy complications and the facilitation of HIV transmission and acquisition. The increasing resistance of microorganisms to drugs used in therapy is remarkable, since women report the recurrence of these infections and associated comorbidities. Different resistant mechanisms already described for the drugs used in the therapy against Trichomonas vaginalis, Candida spp., and Gardnerella vaginalis, as well as aspects related to pathogenesis and treatment, are discussed in this review. This study aims to contribute to drug design, avoiding therapy ineffectiveness due to drug resistance. Effective alternative therapies to treat vaginitis will reduce the recurrence of infections and, consequently, the high costs generated in the health system, improving women's well-being.

Stopping sperm in their tracks

An automated high-throughput platform can screen for molecules that change the motility of sperm cells and their ability to fertilize.

A phenotypic screening platform utilising human spermatozoa identifies compounds with contraceptive activity

There is an urgent need to develop new methods for male contraception, however a major barrier to drug discovery has been the lack of validated targets and the absence of an effective high-throughput phenotypic screening system. To address this deficit, we developed a fully-automated robotic screening platform that provided quantitative evaluation of compound activity against two key attributes of human sperm function: motility and acrosome reaction. In order to accelerate contraceptive development, we screened the comprehensive collection of 12,000 molecules that make up the ReFRAME repurposing library, comprising nearly all the small molecules that have been approved or have undergone clinical development, or have significant preclinical profiling. We identified several compounds that potently inhibit motility representing either novel drug candidates or routes to target identification. This platform will now allow for major drug discovery programmes that address the critical gap in the contraceptive portfolio as well as uncover novel human sperm biology.

Photocatalytic H2-Evolution by Homogeneous Molybdenum Sulfide Clusters Supported by Dithiocarbamate Ligands

Irradiation at 460 nm of [Mo₃(μ₃-S)(μ₂-S₂)₃(S₂CNR₂)₃]I ([2a]I, R = Me; [2b]I, R = Et; [2c]I, R = ⁱBu; [2d]I, R = CH₂C₆H₅) in a mixed aqueous-polar organic medium with [Ru(bipy)₃]²⁺ as photosensitizer and Et₃N as electron donor leads to H₂ evolution. Maximum activity (300 turnovers, 3 h) is found with R = ⁱBu in 1:9 H₂O:MeCN; diminished activity is attributed to deterioration of [Ru(bipy)₃]²⁺. Monitoring of the photolysis mixture by mass spectrometry suggests transformation of [Mo₃(μ₃-S)(μ₂-S₂)₃(S₂CNR₂)₃]⁺ to [Mo₃(μ₃-S)(μ₂-S)₃(S₂CNR₂)₃]⁺ via extrusion of sulfur on a time scale of minutes without accumulation of the intermediate [Mo₃S₆(S₂CNR₂)₃]⁺ or [Mo₃S₅(S₂CNR₂)₃]⁺ species. Deliberate preparation of [Mo₃S₄(S₂CNEt₂)₃]⁺ ([3]⁺) and treatment with Et₂NCS₂^1- yields [Mo₃S₄(S₂CNEt₂)₄] (4), where the fourth dithiocarbamate ligand bridges one edge of the Mo₃ triangle. Photolysis of 4 leads to H₂ evolution but at ∼25% the level observed for [Mo₃S₇(S₂CNEt₂)₃]⁺. Early time monitoring of the photolyses shows that [Mo₃S₄(S₂CNEt₂)₄] evolves H₂ immediately and at constant rate, while [Mo₃S₇(S₂CNEt₂)₃]⁺ shows a distinctive incubation prior to a more rapid H₂ evolution rate. This observation implies the operation of catalysts of different identity in the two cases. Photolysis solutions of [Mo₃S₇(S₂CNⁱBu₂)₃]⁺ left undisturbed over 24 h deposit the asymmetric Mo₆ cluster [(ⁱBu₂NCS₂)₃(μ₂-S₂)₂(μ₃-S)Mo₃](μ₃-S)(μ₃-η²,η¹-S',η¹-S″-S₂)[Mo₃(μ₂-S)₃(μ₃-S)(S₂CNⁱBu₂)₂(μ₂-S₂CNⁱBu₂)] in crystalline form, suggesting that species with this hexametallic composition and core topology are the probable H₂-evolving catalysts in photolyses beginning with [Mo₃S₇(S₂CNR₂)₃]⁺. When used as solvent, N,N-dimethylformamide (DMF) suppresses H₂-evolution but to a greater degree for [Mo₃S₄(S₂CNEt₂)₄] than for [Mo₃S₇(S₂CNEt₂)₃]⁺. Recrystallization of [Mo₃S₄(S₂CNEt₂)₄] from DMF affords [Mo₃S₄(S₂CNEt₂)₄(η¹,κO-DMF)] (5), implying that inhibition by DMF arises from competition for a Mo coordination site that is requisite for H₂ evolution. Computational assessment of [Mo₃S₄(S₂CNMe₂)₃]⁺ following addition of 2H⁺ and 2e^- suggests a Mo(H)-μ₂(SH) intermediate as the lowest energy species for H₂ elimination. An analogous pathway may be available to the Mo₆ cluster via dissociation of one end of the μ₂-S₂CNR₂ ligand, a known hemilabile ligand type, in the [Mo₃S₄]⁴⁺ fragment.

Substituted carbamothioic amine-1-carbothioic thioanhydrides as novel trichomonicidal fungicides: Design, synthesis, and biology

Sexually transmitted diseases like trichomoniasis along with opportunistic fungal infections like candidiasis are major global health burden in female reproductive health. In this context a novel non-nitroimidazole class of substituted carbamothioic amine-1-carbothioic thioanhydride series was designed, synthesized, evaluated for trichomonacidal and fungicidal activities, and was found to be more active than the standard drug Metronidazole (MTZ). Compounds were trichomonicidal in the MIC ranges of 4.77-294.1 μM and 32.46-735.20 μM against MTZ-susceptible and -resistant strains, respectively. Further, compounds inhibited the growth of at least two out of ten fungal strains tested at MIC of 7.50-240.38 μM. The most active compound (20) of this series was 3.8 and 9.5 fold more active than the MTZ against the two Trichomonas strains tested. Compound 20 also significantly inhibited the sulfhydryl groups present over Trichomonas vaginalis and was found to be more active than the MTZ in vivo. Further, a docking analysis carried out with cysteine proteases supported their thiol inhibiting ability and preliminary pharmacokinetic study has shown good distribution and systemic clearance.

Recent developments in anti-Trichomonas research: An update review

Trichomonas vaginalis is a major non-viral sexually-transmitted infection resulted into serious obstetrical and gynecological troubles. The increasing resistance to nitroimidazole therapy and recurrence makes it crucial to develop new drugs against trichomoniasis. Over the past few years, a large number of research articles highlighting the synthetic and natural product research to combat Trichomonas vaginalis have been published. Electronic databases were searched to collect all data from the year 2006 through June 2017 for anti-Trichomonas activity potential of synthetic and natural products. This review article put together the synthetic and natural product research to find out an effective metronidazole alternative to cure trichomoniasis.

2-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study

Trichomoniasis is the most prevalent, non-viral sexually transmitted diseases (STD) caused by amitochondriate protozoan Trichomonas vaginalis. Increased resistance of T. vaginalis to the marketed drug Metronidazole necessitates the development of newer chemical entities. A library of sixty 2-methyl-4/5-nitroimidazole derivatives was synthesized via nucleophilic ring opening reaction of epoxide and the efficacies against drug-susceptible and -resistant Trichomonas vaginalis were evaluated. All the molecules except two were found to be active against both susceptible and resistant strains with MICs ranging 8.55-336.70 μM and 28.80-1445.08 μM, respectively. Most of the compounds were remarkably more effective than the standard Metronidazole. This study analyzes the in vitro and in vivo activities of the new 5-nitroimidazoles, which were found to be safe against human cervical HeLa cells with good selectivity index. The exploration of SAR by the synthesis of four different prototypes and 3D-QSAR study has shown the importance of prototype 1 over other prototypes.